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Abstract: Prescriptions for opioid analgesics to manage moderate-to-severe chronic noncancer 
pain have increased markedly over the last decade, as have postmarketing reports of adverse 
events associated with opioids. As an unintentional consequence of greater prescription opioid 
utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious 
risks associated with all opioid analgesics. In response to these concerns, the Food and Drug 
Administration announced the requirement for a class-wide Risk Evaluation and Mitigation 
Strategy (REMS) for long-acting and extended-release (ER) opioid analgesics in April 2011. 
An understanding of the details of this REMS will be of particular importance to primary care 
providers. The class-wide REMS is focused on educating health care providers and patients on 
appropriate prescribing and safe use of ER opioids. Support from primary care will be neces-
sary for the success of this REMS, as these clinicians are the predominant providers of care 
and the main prescribers of opioid analgesics for patients with chronic pain. Although currently 
voluntary, future policy will likely dictate that providers undergo mandatory training to continue 
prescribing medications within this class. This article outlines the elements of the class-wide 
REMS for ER opioids and clarifies the impact on primary care providers with regard to training, 
patient education, and clinical practice.
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Introduction
Prescription opioid analgesics have gained acceptance as effective treatments for 
moderate-to-severe chronic noncancer pain in properly selected patients.1,2 In 2009, 
approximately 23 million prescriptions of the extended-release (ER) opioid class 
were dispensed to more than 3.8 million unique patients.3 However, an unintentional 
consequence of greater prescription opioid utilization has been the parallel increase 
in misuse, abuse, and overdose, which are serious risks associated with all opioid 
analgesics.4–6
The Food and Drug Administration (FDA) has recognized the substantial risks 
associated with improper use of ER opioid formulations, given the large amount of 
active ingredient contained within a dose and the prolonged time to elimination.7–11 
Under the authority of the Food and Drug Administration Amendments Act of 2007, 
and as a result of stakeholder, industry, public, and advisory committee meetings held 
over several years, in April 2011 the FDA announced a class-wide Risk Evaluation and 
Mitigation Strategy (REMS) for ER opioid analgesics.12 A REMS is a required risk 
management plan that utilizes tools beyond routine labeling to ensure that the benefits 
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of a medication outweigh the risks.13 The intent of the class-
wide REMS is to ensure that the therapeutic benefits of ER 
opioid formulations continue to outweigh the risks, particu-
larly addiction, unintentional overdose, and death resulting 
from inappropriate prescribing, abuse, and misuse.12 Although 
provider participation in this REMS is currently voluntary to 
prescribe these drugs, the FDA and the US Government are 
pursuing legislation to mandate prescriber education as part of 
Drug Enforcement Administration licensing or renewal.8,14
The requirements of the class-wide REMS for ER   opioids 
are particularly relevant to primary care providers, who 
prescribe approximately half of these medications3 and thus 
represent a key point of intervention for risk management 
and safe use. This article briefly reviews the scope of public 
health issues related to prescription opioids, describes the 
class-wide REMS for ER opioids, and answers a few common 
questions regarding this policy. Understanding this REMS 
will help clinicians navigate the rapidly evolving landscape 
for prescribing opioids.
Overdose
Drug overdose deaths have increased each year since 1970, 
and rates of overdose have increased five-fold since 1990.4 In 
2007, for example, more than 27,000 people died from unin-
tentional drug overdose, ranking second only to car accidents 
as the leading cause of unintentional death due to injury in the 
US.4 Although rates of overdose have increased for illicit drugs 
such as cocaine and heroin, the most dramatic increase has 
been observed with prescription opioid medications.4 Recent 
epidemiologic data inclusive of patients with chronic noncancer 
pain, chronic cancer pain, and acute pain indicate an increased 
risk of overdose and overdose-related deaths in patients pre-
scribed $50 mg morphine equivalent per day.15,16 In chronic 
pain patients receiving $100 mg morphine equivalent per day, 
the risk of overdose death was more than seven times that of 
chronic pain patients receiving ,20 mg per day.15
Misuse and abuse
In 2009, approximately 5 million people reported prescrip-
tion opioid abuse.5 In persons 12 years or older, the number 
of first-time abusers of prescription opioids was nearly as 
common as the number of first-time abusers of marijuana.5 
In patients receiving opioids for chronic pain conditions, 
estimates of the prevalence of abuse in pain management 
settings range from 12% to 43%.17–20 Furthermore, in primary 
care chronic pain patients receiving long-term opioid therapy, 
addiction was four times more likely compared with rates in 
the general population.21
In this same patient population, 80% of patients report 
at least one lifetime aberrant drug behavior (eg, request for 
early refills, unauthorized dose escalation).22 Furthermore, 
those who engaged in certain aberrant behaviors (purposely 
oversedating oneself, using opioids for nonpain reasons, 
escalating dose without authorization, or feeling intoxicated 
from opioid administration) were approximately 50 times 
more likely to have opioid addiction.21 Certain patient 
characteristics may also predict abuse, such as a history of 
substance use or comorbid psychological conditions, lending 
weight to the clinical value of utilizing risk assessment prior 
to initiating opioid therapy.23–27
A considerable majority (88%) of persons who abuse 
prescription opioids obtain them from a friend, relative, or a 
single health care provider (Figure 1).5 Furthermore, 18% of all 
persons who abuse a prescription opioid indicate that the drug 
was obtained from a single physician. Of the 55% of cases in 
which the drug was obtained from a friend or family member 
for free, that friend or relative obtained the prescription from 
a single health care provider more than 80% of the time.5 Safe 
Drug dealer/Stranger 5%
Single health care
professional 18%
Internet <1% Other <7%
Friend/Relative (bought/stole) 15% Friend/Relative (free) 55%
Figure 1 Sources of prescription opioid analgesics. Data from US Department of Health and Human Services.5
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and appropriate prescribing practices are therefore fundamental 
to any risk mitigation effort associated with prescribing opioid 
analgesics (see Appendix 1).  Accordingly, counseling patients 
on the importance of protecting their medication from theft 
and never sharing with others is critical.
Class-wide REMS for ER opioids
Overview of REMS
A REMS may be required to ensure that the benefits 
of a medication outweigh the risks.13 Each REMS may 
have up to five components: (1) medication guide; 
Table 1 Potential components of a REMS13,39
Componentsa Purpose Content and potential requirements Examples of implementation
Medication  
guide
Patient education •    Product-specific risks and safety  
information
•    Distributed at the pharmacy to patients 
when dispensing or filling a medication
Communication  
plan
Provider education •  Importance of the REMS 
•  Product-specific risks 
•    Protocols for safe use  
(eg, patient monitoring)
•  “Dear Health Care Professional” letters 
•  Professional society venue
ETASU Safe access to medications  
that would otherwise  
be unavailable
Potential elements:b 
•    Provider training, experience,  
or special certification to prescribe
•    Provider training, experience,  
or special certification to dispense
•    Dispense only in certain health care  
settings
•    Dispense only to patients with safe-use  
documentation
•    Perform monitoring and follow-up
•  Patient enrollment in a registry
•    Providers demonstrate ability to diagnose 
and an understanding of the risks and 
benefits; may act as a prerequisite for 
prescribing
•    Personnel dispensing the medication 
demonstrate an understanding of risks 
and benefits and/or agree to dispense only 
after receiving authorization
•  Medication is dispensed only in the hospital 
•    Medication is given only to patients with 
safe-use documentation of counseling or 
appropriate laboratory results
•    Monitoring is carried out at specific time 
points to prevent a serious risk
•    Registry documents adherence to safe-use 
conditions or appropriate monitoring  
(eg, S.T.E.P.S. for thalidomide access)c,28
Implementation  
systemd
If a REMS includes certain  
ETASU, the REMS may also  
require an implementation  
system to pre-emptively  
ensure compliance
•    Ensure compliance with certification  
prior to prescribing or dispensing
•    Restrict dispensing only in authorized  
safe-use health care settings or patients
•    Restrict distribution only to  
preauthorized entities
•    Validated and secure database of 
prescribers, pharmacies, and health care 
settings to verify certification requirements 
prior to prescribing and dispensing
•    Manufacturer conducts periodic audits of 
prescribers, pharmacies, and health care 
settings to ensure compliance with safe-
use conditions prior to dispensing
•    Manufacturer conducts periodic audits 
of shipment or distribution systems to 
ensure that only preauthorized entities 
(eg, prescribers, pharmacies, health care 
settings) receive the medication
Timetable for  
submission of  
assessmentse
Determine whether REMS  
is meeting desired goals
•    Periodic assessments of the  
effectiveness of the overall program  
and each component
•    Survey of provider knowledge of product 
risks and safe-use conditions
•    Survey for appropriate patient use to 
prevent risk
•    Survey of medication use (eg, provider 
specialty, indication)
•    Surveillance to detect rates of specific 
serious adverse events
Notes: aA REMS may not require all five components, and can be approved with only those that sufficiently mitigate the risk; ball elements may not be required if REMS is 
approved with ETASU; cS.T.E.P.S. provider and patient registry to prevent fetal exposure and reduce risk of serious birth defects; dfor REMS that includes certain ETASU (see 
FDA Guidance, 505–1(f)(3)(B)(C)(D)), the implementation system is designed to monitor and evaluate the REMS and allows the ability to improve the REMS implementation. 
A critical part of the implementation system is that the FDA may require limited distribution of the product (ie, the product is distributed only when safe-use conditions are met, 
such as only to certified prescribers, pharmacies, or health care settings, or only to patients who meet the requirements of the REMS); erequired component of all REMS.
Abbreviations: ETASU, elements to assure safe use; FDA, Food and Drug Administration; REMS, Risk Evaluation and Mitigation Strategy; S.T.E.P.S., System for Thalidomide 
Education and Prescribing.
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(2)   communication plan; (3) elements to assure safe use; 
(4) implementation system; and (5) timetable for submission 
of assessments (Table 1).13,39 Each REMS is individualized 
and approved with those components that address a product’s 
therapeutic profile (Figure 2).13,29
History and requirements of class-wide 
REMS for ER opioids
The FDA indicated a need for a class-wide REMS for ER 
opioids as early as 2009.12,30 In 2010, product-specific, 
interim REMS were approved for the ER formulation of 
hydromorphone (Exalgo®; Mallinckrodt Inc, Hazelwood, 
MO), a novel formulation of controlled-release oxycodone 
(OxyContin®; Purdue Pharma LP, Stamford, CT), and trans-
dermal buprenorphine (Butrans®; Purdue Pharma LP).29 
These programs provide patient education through a medica-
tion guide and health care professional training (eg, training 
on appropriate prescribing practices).29 In April 2011, the 
FDA officially announced the class-wide REMS for ER 
opioids, designed to mitigate serious risks of opioid-related 
adverse outcomes through provider training and patient 
education (see Appendix 2).12 The release of this policy was 
closely coordinated with the White House Office of National 
Drug Control Policy and formed an integral part of the com-
prehensive Prescription Drug Abuse Prevention Plan.14 The 
expected requirements of the new class-wide REMS for ER 
opioids are similar to those of the previously approved REMS 
for products in this class.12 However, in order to streamline 
provider and patient education and to decrease the burden on 
the health care   system, all products within the ER opioid class 
will have the same REMS components.12 These components 
are discussed in greater detail in the following sections, with 
regard to the provider and patient perspectives.
Medication guide
A patient medication guide will describe risks (eg, abuse, 
overdose) and safe use, and stress adherence to the prescribed 
dosing regimen.12 In addition to specific information on safe 
and effective use of the particular opioid, the medication guide 
will include common language for all products in the class.12
Medication guide
Communication plan
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First medication guide: Treximet®
(sumatriptan and naproxen sodium),
April 15, 2008 
First ETASU with implementation system:
Nplate® (romiplostim) for subcutaneous injection,
August 22, 2008 
First ETASU without implementation system:
EXALGO® (hydromorphone HCI)
Extended-Release Tablets CII,
March 1, 2010 
2010 2011
First communication plan: 
ADVAIR Diskus® (fluticasone propionate
and salmeterol inhalation powder),
April 30, 2008 
Figure 2 Cumulative approved Risk Evaluation and Mitigation Strategy (REMS) components, 2008–2011.29
Notes: Data based on Food and Drug Administration-approved REMS (last updated December 12, 2011). All approved REMS require a timetable for submission of 
assessments. A total of 199 products have been approved with REMS since 2008; 81 products were subsequently released from a REMS and are not included here.29
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The content of the class-wide medication guide may 
be similar to past ER opioid medication guides and out-
line symptoms of overdose and the risks associated with 
physically manipulating or tampering with the product (eg, 
breaking, chewing, or crushing the tablet), as well as the 
risk of sharing medications with others.31–33 Patients are also 
advised to store medications in a safe place to prevent theft 
or accidental exposure, and to dispose of unused medications 
properly.31–33 Most current sources suggest flushing unused 
medications down the toilet, or disposing of them in the 
trash in an inconspicuous manner.34,35 Furthermore, patients 
are instructed to report adverse events and are warned of 
the risks of concomitant use of other central nervous system 
depressants, alcohol, or illegal drugs.31–33
Elements to assure safe use
Manufacturers will be required to ensure that training is 
provided to all prescribers of ER opioids.12 The FDA has 
specified the content of the education program to include: 
(1) general information for safe opioid prescribing; 
(2)   product-specific information for each opioid within the 
class; and (3) patient counseling.12 To complement patient 
counseling,   providers will be expected to utilize patient mate-
rials, including information on risks, safe use, and storage 
(Table 2).12 The potential content of the training program may 
be accessed at www.fda.gov/downloads/drugs/drugsafety/
information/bydrugclass/UCM251595.pdf.12
To implement provider training, manufacturers will fund 
and collaboratively develop a single set of educational materi-
als applicable to all medications within the ER opioid class. 
However, training will likely be conducted by an accredited 
continuing medical education (CME) provider, where par-
ticipants will be required to complete a subsequent knowl-
edge assessment.12 This approach is intended to facilitate 
prescriber education and reduce the burden of this program 
on the health care system.8,12 Because there will be one set 
of training materials, providers will not have to complete 
separate educational materials and CME certification for each 
drug in this class. This may be analogous to the approach 
of the State of California, which requires all physicians to 
complete CME credits on pain management, appropriate 
care, and treatment of the terminally ill.36
Table 2 Provider training and patient education, class-wide REMS for ER opioids12
Provider training Patient counseling and education
Safe opioid prescribing 
•  Patient selection and assessment 
•  Pharmacokinetics, risks of addiction, abuse, misuse, and other considerations 
•    Managing patients who are taking opioids (eg, adherence, identifying drug-related  
aberrant behaviors)
•  Initiating opioid therapy and dose titration 
•  Maintenance and reassessment over time 
•  Monitoring for misuse and abuse, need for specialized referral 
•  Discontinuation of opioid therapy
Patient materialsa 
•  Adherence and proper administration 
•  Reporting adverse events 
•  Risk of tampering (eg, breaking, chewing, crushing) 
•    Risk of concomitant use with other central nervous system 
depressants, alcohol, or illicit drugs
•  Risks of sharing 
•  Symptoms of overdose 
•  Proper storage, preventing accidental exposure 
•  Preventing theft/loss and avoiding unsafe exposure 
•  Discontinuation of opioid therapy 
•  Purpose/content of patient provider agreement
Product-specific information 
•  Pharmacokinetics and toxicity 
•  Requirements for opioid tolerance for ER formulations 
•  Individual product information and new product information
Patient counseling 
•  Product-specific information 
•  Adherence and proper administration 
•  Reporting adverse events 
•  Risk of tampering (eg, breaking, chewing, crushing) 
•    Risk of concomitant use with other central nervous system depressants,  
alcohol, or illicit drugs
•  Risks of sharing, preventing overdose 
•  Proper storage, preventing accidental exposure 
•  Preventing theft/loss and avoiding unsafe exposure 
•  Discontinuation of opioid therapy 
•  Purpose/content of patient provider agreement
Note: aProviders will be expected to utilize patient education materials as part of counseling. Data from US Food and Drug Administration.12
Abbreviations: ER, extended release; REMS, Risk Evaluation and Mitigation Strategy.
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Timetable for submission of assessments
Regular and periodic assessments to determine whether the 
program is meeting the objectives and goals of REMS will 
be required for the class-wide ER opioid initiative.12 These 
assessments will provide the FDA and manufacturers with 
a tool for deciding whether this class-wide REMS should be 
modified to increase effectiveness.12
Effect of the class-wide REMS
Although training is presently voluntary for health care 
  providers, it may eventually be mandatory for Drug Enforce-
ment Administration licensing or renewal; however, this 
would require a congressional amendment to the Controlled 
Substances Act.14,37 Given the current rates of prescription 
opioid abuse and the need to minimize the serious risks asso-
ciated with ER opioid formulations, active participation is 
essential. Although still under discussion between the FDA 
and manufacturers, there is the potential for providers to 
complete their class-wide REMS education in coordination 
with other general CME training in pain management.38
A key challenge of any effort to reduce risk is not overly 
restricting access for appropriate patients. The FDA has 
stated its intent to collaborate with the pain management 
community to ensure continued access to ER opioids after 
the implementation of the class-wide REMS.8 Ultimately, 
ensuring the success of these programs with continued 
access to these important medications will depend on the 
support of primary care and pain management providers 
and on collaboration among all stakeholders (ie, FDA, drug 
manufacturers or sponsors, CME providers, educators, and 
health care providers).
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Appendix 1
Case study
Patient: 38-year-old male
Diagnosis: Low back pain
History: The patient has a 6-month history of severe low back 
pain following a work-related lifting injury. He has failed 
physical therapy, skeletal muscle relaxants, and epidural 
injections and is not a surgical candidate. He was switched 
to an ER opioid from hydrocodone/APAP, as his doses were 
escalating over time. Despite increases in the ER opioid dose 
over the last 2 months, he is failing to experience adequate 
pain relief. The patient has also been prescribed adjuvant 
medications, including anticonvulsants and antidepressants, 
and has a prior diagnosis of post-traumatic stress disorder.
Clinical considerations: Opioid treatment is not appropri-
ate for all patients. It is important for the physician to order 
appropriate diagnostic tests to evaluate a patient’s underly-
ing pain condition. The physician should consider whether 
nonopioid therapy is likely to be effective. Patients who have 
moderate-to-severe pain that affects functioning or quality 
of life and who present with a favorable risk-benefit balance 
are most likely to be candidates for opioid therapy.1
All patients being considered for opioid therapy should 
provide a thorough history, including family history and 
disclosure of any psychosocial risk factors; patients must also 
undergo a physical examination and appropriate testing. In 
every case, this testing must include a thorough assessment 
of the patient’s risk of substance misuse, abuse, or addiction. 
A number of brief assessment tools can be used to stratify 
patients according to risk, including the Opioid Risk Tool27 
(ORT) and Screener and Opioid Assessment for Patients 
with Pain25 (SOAPP®-R). Given that the patient is a young 
male with low back pain and psychiatric comorbidity, these 
assessment tools will likely indicate at least a moderate risk 
for abuse. If a trial of ER opioid therapy is being considered, 
the physician must evaluate the patient’s recent opioid history. 
Most doses of ER opioids require that the patient be opioid 
tolerant, as defined by taking 60 mg/day oral morphine 
or equivalent for at least 1 week. As the potency of ER 
opioids differs, the physician should take care to select the 
appropriate equianalgesic dose and account for incomplete 
cross-tolerance among opioids. This generally involves a 
reduction in the equianalgesic dose by 25% to 50% upon 
conversion to the new opioid.39 Once it is determined that the 
benefits of continued opioid therapy are likely to outweigh 
the risks, informed consent should be obtained. The physician 
should establish treatment goals and an opioid agreement that 
helps define treatment boundaries and monitor adherence. It 
is critical that the physician counsel the patient on the risks 
associated with opioids, such as respiratory depression, 
concomitant use of other central nervous system   depressants, 
improper storage, and sharing medicine with others. 
Communicating product-specific information to the patient 
is also a key element to reduce overall risk. After treatment is 
initiated, periodic monitoring is important to assess tolerance, 
changes in symptoms, and abuse-related behaviors. If the 
patient exhibits aberrant behaviors (eg, lost prescriptions, 
unsanctioned dose escalations) that are predictive of abuse, 
the physician may want to consider comanagement or 
referral to a specialist. The physician should also consider 
whether discontinuing opioid therapy is a possibility. In 
summary, when considering a trial of opioid therapy, patient 
selection, counseling, and ongoing assessment are essential 
for mitigating risk.
Appendix 2
Commonly asked questions
Which opioid medications fall under the class-wide 
REMS?
All long-acting and ER opioids will be required to have a 
REMS under the new class-wide guidelines. These products 
include Avinza® (morphine sulfate extended-release capsules, 
CII; King Pharmaceuticals, Inc, Bristol, TN), Butrans® 
(buprenorphine transdermal system, CIII; Purdue Pharma 
LP, Stamford, CT), Dolophine® (methadone hydrochloride 
tablets, CII; Roxane Laboratories, Inc, Columbus, OH), 
Duragesic® (fentanyl transdermal system, CII; Janssen Phar-
maceuticals, Inc, Titusville, NJ), Embeda®* (morphine sulfate 
and naltrexone hydrochloride extended-release capsules, CII; 
King Pharmaceuticals, Inc), Exalgo® (hydromorphone HCl 
extended-release tablets, CII; Mallinckrodt Inc, Hazelwood, 
MO), Kadian® (morphine sulfate extended-release capsules, 
CII; Actavis Kadian LLC, Morristown, NJ), MS Contin® 
(morphine sulfate controlled-release tablets, CII; Purdue 
Pharma LP), Nucynta® ER (tapentadol extended-release 
tablets, CII; Janssen Pharmaceuticals, Inc), Opana® ER 
(oxymorphone hydrochloride extended-release tablets, CII; 
Endo Pharmaceuticals Inc, Chadds Ford, PA), Oramorph® 
SR (morphine sulfate sustained-release tablets, CII; Xano-
dyne Pharmaceuticals, Inc, Newport, KY), OxyContin® 
(oxycodone hydrochloride controlled-release tablets, CII; 
Purdue Pharma LP), and Palladone®* (hydromorphone 
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hydrochloride extended-release capsules, CII; Purdue Pharma 
LP). Generic formulations of the above medications also 
require a REMS.
*Not currently marketed in the US.
As a prescriber of long-acting and ER opioids, can I opt 
out of REMS?
Although currently voluntary, completion of educational mod-
ules and a knowledge assessment will eventually be required 
in order to continue prescribing these medications.
What are my obligations to patients under the class-wide 
REMS?
Health care providers will be expected to counsel patients 
on the risks and safe use of prescription ER opioids 
(see Appendix 1: Case study). The class-wide REMS will pro-
vide educational materials that can be distributed to patients 
as part of patient counseling. Topics will include adherence 
and proper administration, safe use and storage of opioids, 
risks of sharing, risk of tampering (eg, breaking, chewing, 
crushing), reporting of adverse events, concomitant use with 
central nervous system depressants, symptoms of overdose, 
discontinuing opioids, and web links at which additional 
information may be found.
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